We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Indivior Plc | LSE:INDV | London | Ordinary Share | GB00BN4HT335 | ORD USD0.50 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.00 | -0.35% | 1,435.00 | 1,454.00 | 1,456.00 | 1,474.00 | 1,437.00 | 1,440.00 | 355,661 | 16:35:08 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 1.09B | 2M | 0.0148 | 982.43 | 1.97B |
From May 2019 to May 2024
SLOUGH, England and RICHMOND, Va., July 31, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that its first half 2019 results press release and investor supplement are now available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.indivior.com.
Key members of Indivior's leadership team led by Shaun Thaxter, Chief Executive Officer, will host a conference call to discuss the results and address questions from qualified analysts and investors at 11:30 a.m. BST (6:30 a.m. EDT) on July 31, 2019.
Access the Live Webcast for the Results Call
This presentation will also be webcast live. The details are below. The webcast link is https://edge.media-server.com/mmc/p/k4988h75. Participants also may access the results presentation telephonically: US participants 1-631-510-7495; international participants +44 (0) 207 1928000. Please reference confirmation code 5287734. A replay of the presentation will be available at www.indivior.com.
About Indivior
Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy while providing education on evidence-based treatment models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavour, and the tagline "Focus on you" makes the Company's commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 800 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more.
View original content to download multimedia:http://www.prnewswire.com/news-releases/indivior-first-half-2019-results-now-available-conference-call-with-leadership-today-300893714.html
SOURCE Indivior
Copyright 2019 PR Newswire
1 Year Indivior Chart |
1 Month Indivior Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
